There are some small risks with this study, both related to the study medication (semaglutide) and the tests. There may also be unforeseen risks.
Semaglutide has been linked to the following side effects:
Nausea (feeling sick)
Low blood sugar levels (when used with insulin or other diabetic medications)
Bloating sensation, constipation
Gastritis, gastro-oesophageal reflux disease
Increased amylase and lipase (pancreatic damage)
Eye complications related to diabetes
Weight loss and loss of appetite
Alterations in taste
Injection site reactions (rash, pain)
Acute pancreatitis (inflammation of the pancreas)
Allergic reactions, including anaphylaxis
Risks to pregnant women: There may be risks to an unborn baby. You must agree to avoid pregnancy for the duration of the study and at least 2 months after finishing semaglutide.
Risks related to study procedures:
Blood bests can be uncomfortable but rarely cause any significant problems. Rarely, people feel light-headed, faint, a blood clot forms, get bruising and/or an infection at the site of the needle stick.
The DXA scans involve exposure to a very small amount of ionising radiation – about the same amount of radiation as a flight from Dublin to Spain. Ionising radiation can cause call damage that may become cancerous many decades after exposure. We are all at risk of developing cancer during our lifetime. The added risk of developing cancer from having the DXA scans in this study is negligible.
The only risk is a mild discomfort that you might feel from the pressure of the scan probe on your abdomen and between the ribs.